Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Capital Expenditures (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Capital Expenditures for 7 consecutive years, with $552000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Capital Expenditures fell 25.41% to $552000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was $1.8 million, a 182.43% increase, with the full-year FY2024 number at $1.7 million, up 189.67% from a year prior.
  • Capital Expenditures was $552000.0 for Q2 2025 at Whitehawk Therapeutics, down from $1.2 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.6 million in Q3 2023 to a low of -$2.6 million in Q4 2023.
  • A 5-year average of $233357.1 and a median of $312500.0 in 2022 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 1582.61% in 2023; the steepest drop was 773.18% in 2023.
  • Whitehawk Therapeutics' Capital Expenditures stood at $46000.0 in 2021, then skyrocketed by 734.78% to $384000.0 in 2022, then crashed by 773.18% to -$2.6 million in 2023, then surged by 147.43% to $1.2 million in 2024, then crashed by 54.98% to $552000.0 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Capital Expenditures are $552000.0 (Q2 2025), $1.2 million (Q4 2024), and -$852000.0 (Q3 2024).